Skip to content

Study · Randomized controlled trial · n = 690 · 2018

9 results

Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study.

Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W, Ma A, Chen Y, Xu M, Xie W, Cheng J, Xie S and 13 more

Show all authors

Shang J, Cheng J, Xie Q, Ding H, Zhang X, Bai L, Zhang M, Wang B, Chen S, Ma H, Ou X, Jia J, You H

Expert opinion on biological therapy1 Jul 2018Cited by 15 (Europe PMC)

PMID30063860 (opens in a new tab)DOI10.1080/14712598.2018.1451511 (opens in a new tab)PepBankPUB-30063860
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, the cumulative incidence of liver decompensation, HCC or death was similar with entecavir plus thymosin α1 and with entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in liver decompensation, liver cancer or death.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLiver decompensation, HCC or death (primary endpoint)
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The cumulative incidence of liver decompensation, HCC, or death were similar between two groups.
    2 context sentences
    Summary · context
    The primary endpoint was defined as liver decompensation, hepatocellular carcinoma (HCC) or death.
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, cumulative incidence of liver decompensation was similar between entecavir plus thymosin α1 and entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in liver decompensation.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCumulative incidence of liver decompensation
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The cumulative incidence of liver decompensation, HCC, or death were similar between two groups.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, cumulative incidence of HCC was similar between entecavir plus thymosin α1 and entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in liver cancer.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCumulative incidence of hepatocellular carcinoma
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The cumulative incidence of liver decompensation, HCC, or death were similar between two groups.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, cumulative incidence of death was similar between entecavir plus thymosin α1 and entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in death.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCumulative incidence of death
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Mortality · Liver
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The cumulative incidence of liver decompensation, HCC, or death were similar between two groups.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, HCC incidence during combination treatment was 1.7% with entecavir plus thymosin α1 and 2.1% with entecavir alone; the authors describe only a tendency to inhibit HCC.

    In plain wordsIn people with hepatitis B cirrhosis, liver cancer was 1.7% with thymosin α1 plus entecavir and 2.1% with entecavir alone; no clear difference.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHCC incidence during Ta-1 combination treatment
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Measurements

    HCC incidence
    1.7%
    combination group
    HCC incidence
    2.1%
    ETV group

    Source sentences

    Summary
    During the Ta-1 combination treatment, the HCC incidence was 1.7% in combination group and 2.1% in ETV group, without new HCC cases developed during week 39 to week 77 in combination group.
    2 context sentences
    Summary · context
    combination therapy with Ta-1 has a tendency to inhibit the development of HCC.
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, virologic response at week 104 was similar between entecavir plus thymosin α1 and entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in virus response at week 104.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeVirologic response at week 104
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The virologic response, serologic response, biochemical response was similar between two groups at week 104.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, serologic response at week 104 was similar between entecavir plus thymosin α1 and entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in blood marker response at week 104.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSerologic response at week 104
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The virologic response, serologic response, biochemical response was similar between two groups at week 104.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In compensated HBV cirrhosis, biochemical response at week 104 was similar between entecavir plus thymosin α1 and entecavir alone.

    In plain wordsIn people with hepatitis B cirrhosis, adding thymosin α1 to entecavir made no clear difference in liver blood tests at week 104.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeBiochemical response at week 104
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    The virologic response, serologic response, biochemical response was similar between two groups at week 104.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.
  9. 09HumanRandomized controlled trialSafety outcome

    In compensated HBV cirrhosis, both entecavir plus thymosin α1 and entecavir alone were reported as well tolerated.

    In plain wordsIn people with hepatitis B cirrhosis, both thymosin α1 plus entecavir and entecavir alone were reported to be well tolerated.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTolerability
    Study

    n = 690

    Comparator
    Entecavir monotherapy
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Both therapies were well-tolerated.
    1 context sentence
    Summary · context
    A total of 690 patients were randomized to receive Ta-1 plus ETV (n = 351) or ETV monotherapy (n = 339) for 52 weeks after 26 weeks of ETV treatment, followed by continued entecavir therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.